Scarica l'app Stockscreener
26.43
0.83%
-0.22
Dopo l'orario di chiusura:
26.43
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
An officer plans to sell 16,141 Maze Therapeutics (MAZE) shares on October 1, 2026. - Stock Titan
7,500 shares sold under a trading plan at Maze Therapeutics (MAZE) after an option exercise. - Stock Titan
An officer proposes selling 34,501 shares held by two trusts at Maze Therapeutics (Nasdaq: MAZE). - Stock Titan
Maze Therapeutics (MAZE) Valuation Turns On Early Pipeline Data Following A Recent Share Price Bounce - Simply Wall Street
Maze Therapeutics, Inc. (MAZE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history - uk.finance.yahoo.com
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? - Yahoo Finance
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now? - Yahoo Finance
Maze Therapeutics Price Target Maintained With a $46.00/Share by BTIG - Moomoo
Maze Therapeutics Initiated at Buy by Citigroup - Moomoo
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - Benzinga
A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $46 to $110 - Moomoo
Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage - Yahoo Finance
Why is Maze Therapeutics stock climbing today? By Investing.com - Investing.com Canada
Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target - Yahoo Finance
BTIG Initiates Maze Therapeutics at Buy With $50 Price Target - Yahoo Finance
The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily
Vertex Kidney Pill Shows Broader Promise, Lifting Rival Maze 25% - finance.biggo.com
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barron's
Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $64 - Moomoo
BTIG reiterates Buy rating on Maze Therapeutics, $46 price target - TradingView
Maze Therapeutics stock hits 52-week low at 22.44 USD By Investing.com - Investing.com India
Maze Therapeutics stock hits 52-week low at 22.44 USD - Investing.com
Maze Therapeutics, Inc. (MAZE) Stock Analysis: A 166.83% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Maze Therapeutics (MAZE) Slips 1.30% to $23.91 as Shares Drift Toward Key SupportRunaway Gap - careplusvn.com
Maze Therapeutics at H.C. Wainwright conference: pipeline nears key tests By Investing.com - Investing.com Canada
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - The Motley Fool
Maze Therapeutics at Citi summit: early data, bigger tests ahead By Investing.com - Investing.com South Africa
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Australia
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com Nigeria
Maze Therapeutics (MAZE) Institutional Ownership 2026 - MarketBeat
Maze therapeutics president, R&D & CMO, sells $254,501 in shares - Investing.com India
Maze Therapeutics (MAZE) R&D chief exits direct stake - Stock Titan
Maze Therapeutics CSBO Atul Dandekar Disposes of 6,434 Shares at $25.81-$27.12 (NASDAQ: MAZE) - Kalkine Media
Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st
Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights - Benzinga
MAZE News | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill
Courtney Phillips Executes 11,000 Zero-Cost Options in Maze Therapeutics (NASDAQ: MAZE) on September 1, 2026 - Kalkine Media
Maze Therapeutics CSBO Atul Dandekar Sells 6,434 Shares to Cover RSU Tax Withholding - Kalkine Media
Maze Therapeutics (NASDAQ: MAZE) officer lines up new stock sale after recent 10b5-1 trades - Stock Titan
Maze Therapeutics Chief Executive Officer Sold Shares Worth Over $593K - TradingView
Maze Therapeutics (MAZE) legal chief sells stock for taxes - Stock Titan
Insider at Maze Therapeutics (MAZE) sells shares to cover taxes - Stock Titan
Maze Therapeutics (MAZE) CEO sells shares to cover taxes - Stock Titan
Maze Therapeutics (MAZE) R&D chief sells shares to cover RSU taxes - Stock Titan
Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - Kalkine
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):